Literature DB >> 15488873

Effect of anti TNFalpha therapy on arterial diameter and wall shear stress and HDL cholesterol.

Concetta Irace1, Gerardo Mancuso, Elio Fiaschi, Angela Madia, Giorgio Sesti, Agostino Gnasso.   

Abstract

It has been recently hypothesized that both TNFalpha and anti TNFalpha treatment have a stimulating effect on nitric oxide synthesis and release. Moreover, an in vitro experiment has demonstrated that HDL-cholesterol binds TNFalpha. Aims of our study were to investigate wall shear stress of peripheral arteries and endothelial function of brachial artery in subjects with Rheumatoid Arthritis (RA) at baseline and after infliximab. Moreover, we evaluated the effect of anti TNFalpha therapy on lipid profile. Ten patients with RA received infliximab therapy at weeks 0, 2 and 6. Lipids and vascular parameters were measured before and the day after each infusion. After the first treatment, FMD increased (3.7 +/- 1.9% versus 17.5 +/- 2.9%, P <0.01) and common carotid and brachial artery diameters decreased (5.9 +/- 0.2 mm versus 5.5 +/- 0.2 mm; 3.5 +/- 0.4 mm versus 3.1 +/- 0.4 mm, respectively, P <0.005). Common carotid and brachial artery wall shear stress increased (21.1 +/- 1.1 dynes/cm2 versus 23.9 +/- 1.4 dynes/cm2; 42.0 +/- 4.7 dynes/cm2 versus 51.6 +/- 5.7 dynes/cm2, P <0.01). Similar results were observed after the second and third infusion. All these parameters returned to pre-treatment level at the following infusion. HDL-cholesterol and apolipoprotein AI significantly decreased after each treatment (1st treatment: 1.4 +/- 0.05 mmol/L versus 1.2 +/- 0.06 mmol/L, P <0.01; 1.73 +/- 0.05 g/L versus 1.57 +/- 0.02 g/L, P <0.03). The present data show vasoconstriction and an increase of wall shear stress in studied arteries after infliximab. HDL cholesterol is reduced by treatment and does not seem to influence FMD.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15488873     DOI: 10.1016/j.atherosclerosis.2004.04.031

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  22 in total

Review 1.  What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.

Authors:  W G Dixon; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2007-01-24       Impact factor: 19.103

2.  Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study.

Authors:  Kristin Angel; Sella A Provan; Magne K Fagerhol; Petter Mowinckel; Tore K Kvien; Dan Atar
Journal:  Am J Hypertens       Date:  2012-03-01       Impact factor: 2.689

Review 3.  A systematic review of the effect of TNF-alpha antagonists on lipid profiles in patients with rheumatoid arthritis.

Authors:  Eduardo Nicolas Pollono; Maria A Lopez-Olivo; Juan Antonio Martinez Lopez; Maria E Suarez-Almazor
Journal:  Clin Rheumatol       Date:  2010-04-10       Impact factor: 2.980

Review 4.  Update of TNF-alpha antagonists and cardiovascular disease in rheumatoid arthritis.

Authors:  Inmaculada del Rincón; Agustín Escalante
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

Review 5.  Acute coronary syndrome after infliximab therapy in a patient with Crohn's disease.

Authors:  Vasilios Panteris; Anna Perdiou; Vasilios Tsirimpis; Demetrios-Georgios Karamanolis
Journal:  World J Gastroenterol       Date:  2006-10-14       Impact factor: 5.742

6.  Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients.

Authors:  Gianluigi Mazzoccoli; Incoronata Notarsanto; Gennaro Davide de Pinto; Mariangela Pia Dagostino; Angelo De Cata; Giuseppe D'Alessandro; Roberto Tarquini; Gianluigi Vendemiale
Journal:  Intern Emerg Med       Date:  2010-09-16       Impact factor: 3.397

7.  Long-term anti-tumour necrosis factor therapy reverses the progression of carotid intima-media thickness in female patients with active rheumatoid arthritis.

Authors:  A Ferrante; A R Giardina; F Ciccia; G Parrinello; G Licata; G Avellone; E Giardina; R Impastato; Giovanni Triolo
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

8.  TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis.

Authors:  Silvia Bosello; Angelo Santoliquido; Angelo Zoli; Cristiana Di Campli; Roberto Flore; Paolo Tondi; GianFranco Ferraccioli
Journal:  Clin Rheumatol       Date:  2007-12-13       Impact factor: 2.980

Review 9.  Role for TNF in atherosclerosis? Lessons from autoimmune disease.

Authors:  Gayle E McKellar; David W McCarey; Naveed Sattar; Iain B McInnes
Journal:  Nat Rev Cardiol       Date:  2009-06       Impact factor: 32.419

Review 10.  Biologic drugs and arrhythmic risk in chronic inflammatory arthritis: the good and the bad.

Authors:  Pietro Enea Lazzerini; Pier Leopoldo Capecchi; Mauro Galeazzi; Franco Laghi-Pasini
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.